What question did this study set out to answer?

This study aims to assess the clinical utility of next-generation sequencing for detecting circulating HPV DNA in cervical cancer.

March 15, 2026

Advancing molecular residual disease detection in cervical cancer through next‐generation sequencing of circulating human papillomavirus DNA

Key Points

This study aims to assess the clinical utility of next-generation sequencing for detecting circulating HPV DNA in cervical cancer.
Used an ultrasensitive next-generation sequencing assay to detect ccfHPV DNA in patients.
Evaluated 141 patients with cervical cancer for the presence of circulating HPV DNA.
Investigated the optimal sampling time points and thresholds for detection.
Found detectable ccfHPV DNA to have prognostic significance in cervical cancer patients.
Improved risk stratification demonstrated beyond traditional clinical factors.
Highlights the need for further studies to validate clinical utility for post-treatment surveillance.

Abstract

Bønløkke et al. demonstrated the prognostic significance of detectable circulating cell‐free human papillomavirus DNA (ccfHPV DNA) in 141 patients with cervical cancer using an ultrasensitive, tumor tissue‐agnostic next‐generation sequencing (NGS)‐based assay. Further prospective study is needed to determine the optimal sampling time point and threshold and to establish the clinical validity and utility of NGS‐based ccfHPV DNA detection in improving risk stratification beyond clinical factors, and for post‐treatment surveillance beyond clinical examination and imaging.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Cancer

Institutions

University of Toronto

Princess Margaret Cancer Centre

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.